OTCMKTS:PHMMF - Pharma Mar Stock Price, News & Analysis

$2.30
+0.02 (+0.88 %)
(As of 08/25/2019 09:00 AM ET)
Today's Range
$2.30
Now: $2.30
$2.33
50-Day Range
$1.68
MA: $1.96
$2.33
52-Week Range
$1.02
Now: $2.30
$2.70
Volume13,000 shs
Average Volume2,486 shs
Market Capitalization$512.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.18
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes Yondelis, an antitumor agent for the treatment of advanced soft tissue sarcomas and for relapsed ovarian cancer. Read More…

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PHMMF
Previous SymbolNASDAQ:PHMMF
CUSIPN/A
CIKN/A
Phone34-91-846-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$200.26 million

Profitability

Miscellaneous

Employees599
Market Cap$512.10 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PHMMF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter.


Pharma Mar (OTCMKTS:PHMMF) Frequently Asked Questions

What is Pharma Mar's stock symbol?

Pharma Mar trades on the OTCMKTS under the ticker symbol "PHMMF."

Has Pharma Mar been receiving favorable news coverage?

Headlines about PHMMF stock have trended positive recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pharma Mar earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Pharma Mar.

Who are some of Pharma Mar's key competitors?

What other stocks do shareholders of Pharma Mar own?

Who are Pharma Mar's key executives?

Pharma Mar's management team includes the folowing people:
  • Dr. José María Fernández Sousa-Faro Ph.D., Founder, Exec. Chairman, CEO & Pres
  • Mr. Pedro Fernández Puentes, Exec. Vice-Chairman
  • Mr. Juan Carlos-Torres Carretero, Founder (Age 70)
  • Ms. María Luisa de Francia Caballero, Chief Financial Officer
  • Mr. Pascal Besman, Chief Operating Officer

How do I buy shares of Pharma Mar?

Shares of PHMMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharma Mar's stock price today?

One share of PHMMF stock can currently be purchased for approximately $2.30.

How big of a company is Pharma Mar?

Pharma Mar has a market capitalization of $512.10 million and generates $200.26 million in revenue each year. Pharma Mar employs 599 workers across the globe.View Additional Information About Pharma Mar.

What is Pharma Mar's official website?

The official website for Pharma Mar is http://www.pharmamar.com/.

How can I contact Pharma Mar?

Pharma Mar's mailing address is Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770. The company can be reached via phone at 34-91-846-6000.


MarketBeat Community Rating for Pharma Mar (OTCMKTS PHMMF)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Pharma Mar and other stocks. Vote "Outperform" if you believe PHMMF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHMMF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel